Navigation Links
Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL

SAN FRANCISCO, Dec. 7 /PRNewswire-FirstCall/ -- Results of the Phase 2 clinical trial of R788 (fostamatinib disodium) in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma (NHL) will be presented today at a plenary session during the 50th Annual American Society of Hematology (ASH) Meeting. The results affirm preliminary reports that Rigel's oral Syk inhibitor is well-tolerated by these patients and shows therapeutic benefit in patients suffering from diffuse large B-Cell lymphoma (DLBCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Rigel will host a conference call today at 4:00 p.m. PST to discuss these results (see conference call details below).

"Despite the fact that the patients enrolled in this trial had advanced disease and had failed treatment with marketed therapies, a significant number of them were particularly responsive to Syk inhibition with R788," said Jonathan Friedberg, M.D., M.S.Sc., Associate Professor of Medicine, James P. Wilmot Cancer Center, University of Rochester and lead investigator for the clinical trial. "I am encouraged by this data and look forward to conducting additional trials of R788, particularly in patients with DLBCL and CLL/SLL types of non-Hodgkin's lymphomas," he added.

              Phase 2 Results: R788 in NHL Patients - 200 mg bid

                                       Patients      Overall     % Patients
    NHL Type                        (total n=68)     Response     Responding
    DLBCL                                23               5           22%
    Follicular NHL                       21               2           10%
    Other NHL*                           24
      - CLL/SLL                          11               6           55%
      - MCL                               9               1           11%

    * Other NHL patients included 11 with CLL/SLL, 9 with Mantle cell NHL, 1
      with Lymphoplasmacytic NHL and 3 with MALT/MZL.  The 4 patients with
      Lymphoplasmacytic and MALT are not referenced in the above table as
      they did not show a response to treatment.

Clinical Trial Design

This clinical trial was conducted in two Phases. Phase 1 included a small group of patients and resulted in the selection of the dosing regimen employed in Phase 2. Nearly equal numbers of patients were enrolled in the three Phase 2 groups that included, respectively: DLBCL, follicular lymphoma (FL) and other non-Hodgkin's lymphomas (specifically CLL/SLL, MCL, MALT, marginal zone, and lymphoplasmacytic). Prior to enrollment in the R788 trial, all patients enrolled in the clinical trial had received various standard-of-care treatments for their disease, including combination chemotherapy, and had failed to respond to those therapies or suffered a relapse of the disease. A total of 68 patients received 200 mg PO bid (orally, twice daily) of R788 until disease progression occurred. Response to treatment was evaluated using standard NHL response criteria (The Cheson Criteria). Treatment-related adverse events included cytopenias, fatigue, diarrhea/abdominal discomfort and hypertension. Most adverse events were mild to moderate and were reversible. Four patients are continuing to receive R788, including 2 from the CLL/SLL group and 1 from the DLBCL group.

B-Cell Lymphoma and Syk Inhibition

Lymphoma affects an estimated 500,000 people in the United States, with 332,000 of them suffering from non-Hodgkin's lymphoma. Diffuse large B-cell lymphoma is the most common type of NHL and is generally categorized as aggressive, marked by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow and other organs. A variety of treatment options for NHL exist, including chemotherapy and radiation, but the five-year survival rate for NHL patients is estimated to be around 50%. Even for those who respond to treatment, recurrence of the disease is common.

A growing field of research on the cellular signaling associated with these lymphomas indicates that inhibiting Syk (spleen tyrosine kinase) in aberrant cells may control spread of the disease. Two additional research studies on the topic are also being presented at the ASH meeting. They are: Abstract 377, entitled "BCR, Signaling Diversity in Human Lymphoma B Cells Correlates with Follicular Lymphoma Patient Clinical Outcomes" and Abstract 802, entitled "BCL-6 Regulates Tonic BCR Signaling in Diffuse Large B-Cell Lymphomas." Further information on R788 in B-cell lymphoma is available at Rigel's website:

Conference Call and Webcast Information

To access the live call, please dial 800-561-2693 (domestic) or 617-614-3523 (international) 10 minutes prior to the start time and use the passcode 36883961. A replay of the call will be available, in webcast and podcast formats, at approximately 6:00 p.m. PST on December 7, 2008 through December 14, 2008. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and use the passcode 47095093. The conference call will also be webcast live and can be accessed from Rigel's website at Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.

About Rigel (

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

     Contact: Raul Rodriguez
     Phone: 650.624.1302

     Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
     Phone: 650.430.3777

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. OnKua, Launches Phase I Of "Phyzoom" A Web-Based Physician Marketing And Customer Relationship Management Product
2. MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
3. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
4. SimQuest Awarded Phase 2 Contract from Office of the Secretary of Defense to Develop Pandemic Influenza Training Program
5. Neuromed Completes Enrollment for Phase 3 Chronic Low Back Pain Clinical Trial of NMED-1077
6. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
7. Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
8. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
9. Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data
10. Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
11. Ceregene Phase 2 Clinical Trial for Alzheimers Disease to be Funded by $5.4 Million Grant From National Institutes of Health
Post Your Comments:
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... An ... of life in the womb. "My last baby had high blood pressure due to ... for mothers to protect their babies from noise pollution as well as radio waves ...
(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... two new additions to its industry-leading suite of automated breast density assessment ... North America (RSNA) meeting, November 29-December 4, 2015 (South Hall booth #2377). ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... one of the leading plastic surgery practices in Florida, is proud to announce ... consult for surgical innovations giant Ethicon Inc., a Johnson & Johnson Company. , ...
(Date:11/30/2015)... , ... November 30, 2015 , ... The successful filing ... pharmaceutical company. Because it is so important to this key industry segment, Regis Technologies ... your IND Filing” on December 4th at 11am EST. , Federal law does not ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... assets of DataTrade Solutions Inc., a Healthcare IT consulting, development and support company. ... programming and technical experience available within DataTrade to extend the services currently provided ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Fla. , Nov. 30, 2015   The ... (the Institute) announced today that it has finalized a ... start-up company with technology developed at Florida State University. ... research, and bridges early funding gaps for companies spinning ... research institutions. --> ...
(Date:11/30/2015)... India , November 30, 2015 ... --> adds ... trends for 2010 - 2015 with ... for a range of deal types, ... and strategic alliances. ...
(Date:11/30/2015)... PUNE, India , November 30, 2015 ... new market research report "Dental Lasers Market by Product (Soft ... Treatment, Periodontitis), End User (Hospitals, Clinics), and Geography - Global ... USD 224.7 Million by 2020, at a CAGR of 5.2% ... , Browse 140 market data Tables and 62 Figures spread ...
Breaking Medicine Technology: